AGN-199201

AGN-199201 is a synthetic retinoid and a selective agonist of the retinoic acid receptor gamma (RARγ). Developed by Allergan, the compound was designed to target the primary RAR isoform found in human skin, which plays a crucial role in regulating keratinocyte proliferation and differentiation. By binding to RARγ, AGN-199201 modulates the transcription of retinoid-responsive genes, leading to effects such as reduced comedone formation and decreased inflammatory responses. This selectivity was intended to optimize therapeutic outcomes for dermatological conditions like acne and psoriasis while potentially reducing the systemic toxicity or off-target effects associated with pan-RAR agonists. Although it has been extensively used as a pharmacological tool in preclinical studies to investigate retinoid signaling, it has not transitioned into a widely recognized clinical product.

Other names

oxymetazoline hydrochloride cream 1%